SBHMY (Sino Biopharmaceutical) Inventories, Finished Goods : $0 Mil (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sino Biopharmaceutical Inventories, Finished Goods?

Sino Biopharmaceutical's quarterly finished goods increased from Jun. 2023 ($0 Mil) to Dec. 2023 ($124 Mil) but then declined from Dec. 2023 ($124 Mil) to Jun. 2024 ($0 Mil).

Sino Biopharmaceutical's annual finished goods declined from Dec. 2021 ($153 Mil) to Dec. 2022 ($83 Mil) but then increased from Dec. 2022 ($83 Mil) to Dec. 2023 ($124 Mil).

Sino Biopharmaceutical Inventories, Finished Goods Historical Data

The historical data trend for Sino Biopharmaceutical's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Inventories, Finished Goods Chart

Sino Biopharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Inventories, Finished Goods

Get a 7-Day Free Trial

66.30

153.39

82.81

123.85

Sino Biopharmaceutical Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Inventories, Finished Goods	Get a 7-Day Free Trial															82.81	-	123.85	-	-

Sino Biopharmaceutical Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Sino Biopharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBHMY) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

SBMFF:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.